Jonathan Delos Reyes, MD
Rheumatology · Denton, TXNPI 1780633255
Payments from drug & device makers
Across 723 payments — averaging $21.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- UCB, Inc.$3K
- Amgen$2K
- E.r. Squibb & Sons, L.L.C.$1K
- Mallinckrodt Enterprises LLC$865
- Pfizer$845
- plus $4K from 27 others
What the payments were for
- Consulting fees$7004%
- Grants$2402%
- Food & beverage$14,62794%
- Education$360%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 148 | $3,457 |
| UCB, Inc. | 113 | $2,886 |
| Amgen(2 entities) | 128 | $2,074 |
| E.r. Squibb & Sons, L.L.C. | 60 | $1,044 |
| Mallinckrodt Enterprises LLC | 8 | $865 |
| Pfizer | 45 | $845 |
| GSK | 36 | $839 |
| Lilly USA, LLC | 30 | $513 |
| Novartis | 23 | $488 |
| ANI Pharmaceuticals, Inc. | 20 | $361 |
| Boehringer Ingelheim | 11 | $254 |
| Mallinckrodt Hospital Products Inc. | 12 | $248 |
| Radius Health, Inc. | 12 | $222 |
| Johnson & Johnson | 12 | $222 |
| Aurinia Pharma U.S., Inc. | 8 | $167 |
| AstraZeneca(2 entities) | 8 | $148 |
| Sanofi | 8 | $141 |
| Bioventus LLC | 4 | $114 |
| Fresenius Kabi USA, LLC | 4 | $102 |
| Sobi, Inc | 5 | $102 |
| Organon | 6 | $99 |
| Merck | 5 | $73 |
| Pacira Therapeutics, Inc. | 3 | $55 |
| Sandoz | 2 | $54 |
| Genentech USA, Inc. | 2 | $37 |
| Bristol Myers Squibb | 2 | $36 |
| Tersera Therapeutics LLC | 2 | $35 |
| Tonix Medicines, Inc. | 1 | $29 |
| Octapharma USA, Inc. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Fidia Pharma USA Inc. | 1 | $20 |
| Celltrion USA Inc. | 1 | $16 |
| Cumberland Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,603 in reported general payments places this provider in the 65th percentile of 512 rheumatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 33 | $296,109 |
| Taltz AutoinjectorIxekizumab | 26 | $220,580 |
| Humira(Cf) PenAdalimumab | 17 | $133,604 |
| Xeljanz XrTofacitinib Citrate | 17 | $117,419 |
| Orencia ClickjectAbatacept | 18 | $102,475 |
| MethotrexateMethotrexate Sodium | 235 | $6,411 |
| Hydroxychloroquine Sulfate | 124 | $5,988 |
| Pregabalin | 77 | $3,490 |
| Cevimeline Hcl | 13 | $2,835 |
| Duloxetine Hcl | 141 | $2,569 |
| Mycophenolate Mofetil | 18 | $1,246 |
| Diclofenac Potassium | 14 | $1,115 |
| Sulfasalazine DrSulfasalazine | 23 | $1,094 |
| Sulfasalazine | 26 | $970 |
| Pilocarpine Hcl | 19 | $872 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Denton
- Paul PickrellAustin$40.9M
- Atul SinghalMesquite$13.9M
- Shaikh AliTomball$9.8M
- Jitendra VasandaniLubbock$6.4M
- Dhiman BasuColleyville$6.2M
- Tamar BrionezThe Woodlands$5.2M
- Philip WallerHouston$4.9M
- John CushDallas$3.9M
- Sabeen NajamBaytown$3.6M
- Sanjay ChabraEl Paso$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.